Life Sciences Commercial Technology State of the Market 2023

October 2023: Complimentary Abstract / Table of Contents



Our research offerings

This report is included in the following research program(s):

Life Sciences Information Technology, Life Sciences Commercial Technologies

- Amazon Web Services (AWS)
- Application Services
- Artificial Intelligence (AI)
- Asset and Wealth Management
- ▶ Banking and Financial Services Business Process
- ▶ Banking and Financial Services Information Technology
- ▶ Catalyst[™]
- ▶ Clinical Development Technology
- ▶ Cloud and Infrastructure
- Contingent Staffing
- ▶ Contingent Workforce Management
- ► Customer Experience Management Services
- CX Excellence
- CXM Technology
- Cybersecurity
- Data and Analytics
- ▶ Digital Adoption Platforms
- ▶ Digital Services
- ▶ Digital Workplace
- ▶ Employee Experience Management (EXM) Platforms
- ► Employer of Record (EOR)
- ▶ Engineering Research and Development
- ► Enterprise Platform Services
- ► Exponential Technologies
- ► Finance and Accounting

- ► Financial Services Technology (FinTech)
- ▶ GBS Talent Excellence
- Global Business Services
- Google Cloud
- ► Healthcare Business Process
- ► Healthcare Information Technology
- ▶ HealthTech
- ▶ Human Resources
- ▶ Insurance Business Process
- ► Insurance Information Technology
- ► Insurance Technology (InsurTech)
- ▶ Insurance Third-Party Administration (TPA) Services
- ► Intelligent Document Processing
- ▶ Interactive Experience (IX) Services
- ▶ IT Services Excellence
- ► IT Services Executive Insights™
- ▶ IT Talent Excellence
- ▶ Life Sciences Business Process
- ▶ Life Sciences Commercial Technologies
- ▶ Life Sciences Information Technology
- ▶ Locations Insider™
- Marketing Services
- ▶ Market Vista™
- ▶ Microsoft Azure
- ► Modern Application Development (MAD)

- Mortgage Operations
- ► Multi-country Payroll
- ▶ Network Services and 5G
- Oracle Services
- ▶ Outsourcing Excellence
- ▶ Pricing Analytics as a Service
- ▶ Process Mining
- Process Orchestration
- ▶ Procurement and Supply Chain
- Recruitment
- ▶ Retail and CPG Information Technology
- ▶ Retirement Technologies
- ▶ Revenue Cycle Management
- Rewards and Recognition
- ▶ SAP Services
- Service Optimization Technologies
- ► Software Product Engineering Services
- ▶ Supply Chain Management (SCM) Services
- Sustainability Technology and Services
- ▶ Talent Genius™
- ► Technology Skills and Talent
- ► Trust and Safety
- ► Value and Quality Assurance (VQA)

If you want to learn whether your organization has a membership agreement or request information on pricing and membership options, please contact us at info@everestgrp.com

Learn more about our custom research capabilities

Benchmarking

Contract assessment

Peer analysis

Market intelligence

Tracking: providers, locations, risk, technologies

Locations: costs, skills, sustainability, portfolios



Contents

For more information on this and other research published by Everest Group, please contact us:

Durga Amati, Practice Director

Rohit K, Senior Analyst

Panini K, Senior Analyst

1.	Introduction and overview	4
	Research methodology	5
	Background of the research	6
	Everest Group view of commercial technology landscape	7
	Summary of the report	8
2.	Current state of commercial technology in life sciences industry	9
	Snapshot of the life sciences commercial technology market	10
	Key drivers for commercial technology investments in life sciences	12
	Key challenges hindering the adoption of commercial technology in life sciences	13
3.	Disruptive trends in commercial technology	14
	Shift from traditional to hybrid commercial model	16
	Moving beyond traditional Customer Relationship Management (CRM) to focus on Customer Experience Platform (CXP)	18
	Evolution of commercial learning experience platform	20
	Rise of conversational AI	22
	Transformation of medical affairs function	24
	Emergence of niche startups	26
	Veeva and Salesforce part ways	28
4.	Commercial technology supply landscape and implications	29
	Overview of the life sciences commercial technology supply landscape	30
	Implication for platform providers	31
5.	Appendix	32
	• Glossary	33
	Research calendar	34

Background of the research

In the aftermath of the pandemic, industries across the globe have shifted their investment priorities toward delivering personalized Customer Experience (CX), and the life sciences commercial function is no exception. To stay resilient and keep pace with the evolving landscape, the life sciences industry has started to embrace technology to bring differentiation to the end-users. However, the existing tools are outdated and data fragmentation across business functions hampers the enterprises' ability to deliver personalized experiences. Currently, commercial technology in the life sciences industry primarily consists of fundamental technological tools such as CRM, content management systems, and marketing tools, however, these tools serve as repositories of information with limited insights into customers. Hence, enterprises are further augmenting these solutions with advanced technologies such as data and analytics and Al/ML to develop customer-centric solutions that assists in targeted sales and right messaging, eventually boosting business performance and assisting in gaining a competitive edge. These solutions also assist the internal stakeholders (IT departments, sales and marketing team, medical affairs function, sales representatives, etc.) understand customer behavior and evolve their commercial strategies accordingly.

This particular report looks at:

- Current state of commercial technology in the life sciences industry
- Emerging themes in commercial technology
- Supplier landscape and the implications for platform providers

Scope of this report





Providers
Life sciences
(biopharmaceuticals
and medical devices)



Overview and abbreviated summary of key messages

Some of the findings in this report, among others, are:

Overview of life sciences commercial technology market

- The life sciences commercial technology market is poised for a strong annual growth rate of 15%, primarily driven by the shift in priorities of
 enterprises toward providing a personalized customer experience and investing in advanced technologies to unlock actionable real-time
 customer insights
- As enterprises look to stay ahead of the curve by remaining responsive to evolving customer trends through investing in technology, they are
 limited by the presence of legacy IT infrastructure, siloed business functions, and the absence of a proven business cases to justify commercial
 investments


Ever evolving life sciences commercial technology landscape

- Amid the transition from conventional to hybrid commercial models, enterprises are actively seeking to enrich their traditional CRM systems with experience-enhancing capabilities
- The recent event of two life sciences CRM incumbents, Veeva and Salesforce, falling apart has multiple implications for both parties involved and has left enterprises with a variety of options to consider
- Meanwhile, the absence of experiential functionalities in traditional CRM systems has spurred the emergence of niche startups, resulting in a competitive landscape that utilizes advanced technologies (AI/ML) to address unique commercial use cases

Supply eco-system and implications for technology providers

- As traditional CRM providers are enhancing their solutions with accelerators to meet enterprise requirements, niche platform providers have emerged to address specific commercial technology use cases related to end-to-end content management, channel engagement optimization, and commercial learning and training, bridging the gap from CRM to CXP
- However, platform providers face mounting pressure to strengthen their talent and partner ecosystem (system integrators, niche platform providers, data integrators) in order to deliver impactful outcomes

This study offers distinct chapters providing a deep dive into key aspects of life sciences commercial technology market; below are four charts to illustrate the depth of the report



Research calendar

Life Sciences Information Technology

Published P	Planned Current release
Reports title	Release date
Medical Devices Digital Services PEAK Matrix® Assessment 2023	May 2023
Medical Devices Digital Service – Provider Profiles Compendium	May 2023
Life Sciences Decentralized Clinical Trial Platforms State of the Market 2023	June 2023
Life Sciences Decentralized Clinical Trial Products State of the Market 2023	June 2023
Artificial Intelligence (AI) in the Pharmaceutical Industry	May 2023
Life Sciences IT Services (ITS) State of the Market 2023	June 2023
Life Sciences Smart Manufacturing Services PEAK Matrix® Assessment 2023	August 2023
Life Sciences Commercial Technology State of the Market 2023	October 2023
Life Sciences Customer Engagement Platforms (CEP) PEAK Matrix® Assessment 2023	Q4 2023
Life Sciences Customer Engagement Platforms (CEP) – Provider Compendium 2023	Q4 2023
Life Sciences Smart Manufacturing Services – Provider Compendium	Q4 2023
Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2023	Q4 2023
Life Sciences Customer Experience Platform (CXP) Adoption Playbook	Q4 2023
Assessing Enterprise Readiness to Conduct Decentralized Clinical Trials	Q4 2023
Preparing the Landscape for the Next-gen Decentralized Clinical Trials (DCT)	Q4 2023

Note: Click to see a list of all of our published Life Sciences Information Technology







Everest Group is a leading research firm helping business leaders make confident decisions. We guide clients through today's market challenges and strengthen their strategies by applying contextualized problem-solving to their unique situations. This drives maximized operational and financial performance and transformative experiences. Our deep expertise and tenacious research focused on technology, business processes, and engineering through the lenses of talent, sustainability, and sourcing delivers precise and action-oriented guidance. Find further details and in-depth content at www.everestgrp.com.

Stay connected

Dallas (Headquarters)

info@everestgrp.com +1-214-451-3000

Bangalore

india@everestgrp.com +91-80-61463500

Delhi

india@everestgrp.com +91-124-496-1000

London

unitedkingdom@everestgrp.com +44-207-129-1318

Toronto

canada@everestgrp.com +1-214-451-3000

Website

everestgrp.com

Social Media

in @Everest Group

@Everest Group

▶ @Everest Group

Blog

everestgrp.com/blog

This document is for informational purposes only, and it is being provided "as is" and "as available" without any warranty of any kind, including any warranties of completeness, adequacy, or fitness for a particular purpose. Everest Group is not a legal or investment adviser; the contents of this document should not be construed as legal, tax, or investment advice. This document should not be used as a substitute for consultation with professional advisors, and Everest Group disclaims liability for any actions or decisions not to act that are taken as a result of any material in this publication.

NOTICE AND DISCLAIMERS

IMPORTANT INFORMATION. PLEASE REVIEW THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. THROUGH YOUR ACCESS, YOU AGREE TO EVEREST GROUP'S TERMS OF USE.

Everest Group's Terms of Use, available at www.everestgrp.com/terms-of-use/, is hereby incorporated by reference as if fully reproduced herein. Parts of these terms are pasted below for convenience; please refer to the link above for the full version of the Terms of Use.

Everest Group is not registered as an investment adviser or research analyst with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (FINRA), or any state or foreign securities regulatory authority. For the avoidance of doubt, Everest Group is not providing any advice concerning securities as defined by the law or any regulatory entity or an analysis of equity securities as defined by the law or any regulatory entity.

All Everest Group Products and/or Services are for informational purposes only and are provided "as is" without any warranty of any kind. You understand and expressly agree that you assume the entire risk as to your use and any reliance upon any Product or Service. Everest Group is not a legal, tax, financial, or investment advisor, and nothing provided by Everest Group is legal, tax, financial, or investment advice. Nothing Everest Group provides is an offer to sell or a solicitation of an offer to purchase any securities or instruments from any entity. Nothing from Everest Group may be used or relied upon in evaluating the merits of any investment. Do not base any investment decisions, in whole or part, on anything provided by Everest Group.

Products and/or Services represent research opinions or viewpoints, not representations or statements of fact. Accessing, using, or receiving a grant of access to an Everest Group Product and/or Service does not constitute any recommendation by Everest Group that recipient (1) take any action or refrain from taking any action or (2) enter into a particular transaction. Nothing from Everest Group will be relied upon or interpreted as a promise or representation as to past, present, or future performance of a business or a market. The information contained in any Everest Group Product and/or Service is as of the date prepared, and Everest Group has no duty or obligation to update or revise the information or documentation. Everest Group may have obtained information that appears in its Products and/or Services from the parties mentioned therein, public sources, or third-party sources, including information related to financials, estimates, and/or forecasts. Everest Group has not audited such information and assumes no responsibility for independently verifying such information as Everest Group has relied on such information being complete and accurate in all respects. Note, companies mentioned in Products and/or Services may be customers of Everest Group or have interacted with Everest Group in some other way, including, without limitation, participating in Everest Group research activities.